Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04736134 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants | PHASE1 | COMPLETED | 88 | — | — | Mar 3, 2021 | Mar 14, 2024 | May 6, 2024 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| Active Treatment (BMS 986326) IV | EXPERIMENTAL | Intravenous (IV) |
| Active Treatment (BMS 986326) SC | EXPERIMENTAL | Subcutaneous (SC) |
| Placebo IV | PLACEBO_COMPARATOR | - |
| Placebo SC | PLACEBO_COMPARATOR | - |
| Multiple Ascending Dose Placebo SC | PLACEBO_COMPARATOR | Placebo |
| Multiple Ascending Dose SC | EXPERIMENTAL | BMS 986326 SC |
| Name | Type | Description |
|---|---|---|
| BMS-986326 | BIOLOGICAL | Specified dose on specified days |
| Placebo matching BMS-986326 | OTHER | Specified dose on specified days |
| Multiple Ascending Dose SC | BIOLOGICAL | Specified dose on specified days |
| Multiple Ascending Dose Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * In good health, as determined by the investigator based on a physical examination at screening * Body mass index (BMI) ≥ 18 and ≤ 30 kg/m\^2 at screening * Afebrile, with supine systolic blood pressure (BP) ≥ 90 and ≤ 140 mmHg and supine diastolic BP ≥ 50 and ≤ 90 mmHg and hea...